Trial Condition(s):

Hypertension, Pulmonary, Ventricular Dysfunction, Left

A study to test the effects of Riociguat in patients with pulmonary hypertension associated with left ventricular diastolic dysfunction (DILATE)

Bayer Identifier:

14554

ClinicalTrials.gov Identifier:

NCT01172756

EudraCT Number:

2010-018436-41

Terminated/Withdrawn

Trial Purpose

The aim of this study is to assess whether single oral doses of Riociguat safely improve the cardiovascular function in patients with pulmonary hypertension associated with left ventricular diastolic dysfunction

Inclusion Criteria
- Male and female patients with symptomatic pulmonary hypertension due to left ventricular diastolic dysfunction
Exclusion Criteria
- Types of pulmonary hypertension other than group 2.2 of Dana Point Classification

Trial Summary

Enrollment Goal
39
Trial Dates
black-arrow
Phase
2
Could I receive a placebo?
Yes
Products
Adempas (Riociguat, BAY63-2521)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Krankenhaus der Elisabethinen Linz

Linz, Austria, 4010

Status
Completed
 
Locations

Landeskrankenhaus Salzburg

Salzburg, Austria, 5020

Status
Completed
 
Locations

Allgemeines Krankenhaus der Stadt Wien Universitätskliniken

Wien, Austria, 1090

Status
Completed
 
Locations

LKH Graz West

Graz, Austria, 8020

Status
Terminated
 
Locations

Medizinische Universität Graz

Graz, Austria, 8036

Status
Terminated
 
Locations

Vseobecna fakultni nemocnice

Praha 2, Czech Republic, 12808

Status
Completed
 
Locations

Universitätsklinikum Köln

Köln, Germany, 50924

Status
Completed
 

Trial Design